Capricor Therapeutics Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scroll to see more
Capricor Therapeutics, Inc. income statement - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
Revenue & Gross Profit
Revenue22.2725.182.550.240.310.001.67
Cost of Revenue49.9736.4521.8213.578.460.000.00
Gross Profit-27.7025.18-19.270.24-8.150.000.00
Operating Expenses
Research & Development49.9736.4521.8213.578.505.1412.07
Selling, General & Administrative14.8712.3710.437.615.543.604.93
Operating Expenses14.8749.2610.4321.185.548.7417.00
Operating Income-42.56-24.08-29.70-20.94-13.69-8.74-15.33
Other Income/Expense
Interest Income2.201.730.520.060.030.000.00
Interest Expense0.000.000.000.000.000.000.00
Other Income/Expense0.011.790.680.92-0.03-1.100.14
Income
Income Before Tax-40.47-22.29-29.02-20.02-13.66-7.64-15.19
Income Tax Expense0.000.000.000.000.000.000.00
Net Income-40.47-22.29-29.02-20.02-13.66-7.64-15.19
Net Income - Continuous Operations-40.47-22.29-29.02-20.020.000.000.00
Net Income - Discontinued Operations0.000.000.000.000.000.000.00
EBITDA-41.14-23.01-29.16-20.69-13.55-7.47-15.17
EBIT-42.56-24.08-29.70-20.94-13.69-7.64-15.33
Depreciation & Amortization1.430.440.530.250.14-0.130.00
Earnings Per Share
Basic EPS-1.00-1.00-1.00-1.00-1.00--5.00
Diluted EPS-1.00-1.00-1.00-1.00-1.00-2.00-5.00
Basic Shares Outstanding35.2226.7824.5523.0915.573.712.94
Diluted Shares Outstanding35.2226.7824.5523.0915.573.712.94